FMA
MYGN icon

FNY Managed Accounts’s Myriad Genetics MYGN Stock Holding History

FNY Managed Accounts’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-732
Closed -$24.9K – 529
2015
Q2 		$24.9K Buy
+732
New +$24.9K 0.03% 195

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FNY Managed Accounts's MYGN Position: Q3 2015 in Review

FNY Managed Accounts sold out of Myriad Genetics (MYGN) in Q3 2015, closing a stake of 732 shares — an estimated $24.9K sold.

FNY Managed Accounts first reported a position in MYGN in Q2 2015 and held it in 1 quarter. The position peaked at $24.9K in Q2 2015. 234 funds tracked by Wall St. Rank hold MYGN as of Q3 2015.

  • FNY Managed Accounts reported no remaining Myriad Genetics position as of Q3 2015 after selling out during the quarter.
  • FNY Managed Accounts sold 732 Myriad Genetics shares in Q3 2015, an estimated $24.9K.
  • FNY Managed Accounts first reported a position in Myriad Genetics in Q2 2015 and held it in 1 quarter.
  • FNY Managed Accounts's Myriad Genetics position peaked at $24.9K in Q2 2015.
  • 234 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2015.

Based on FNY Managed Accounts's 13F filing for Q3 2015, filed 27 Oct 2015.